engleski

In vivo effects of L-seryl-L-asparaginyl-L-lysine in rats

The L-seryl-L-asparaginyl-L-lysine (SDK), a tripeptide inhibitor of DNA synthesis in rat liver regeneration was further investigated for its possible toxicity and in vivo side effects on liver, kidney pancreas and hearth. It was demonstrated that SDK is not a toxic agent, inducing no hepatocyte impairment or liver damage in rats to which the 10- and 90-fold most active inhibitory doses were administred. Results of glucose, cholesterol, triacyl-glycerols and total proteins in control and SDK treated rats for 14 days showed no statistically significant differences between the groups. The values of total bilirubin, AST and ALT were somewhat higher, and that of AP somewhat lower in SDK treated rats, but not significantly. The selected biochemical tests indicating kidney function (urea, creatinine) showed no significant difference either, whereas the creatinine clearence increase in rats treated by SDK for 14 days was at the limit of significance. The analysis of pancreas function by amylase and glucose showed a slight but not significant decrease in rats treated with SDK. The results of LDH and CK indicating hearth state also suggested that SDK induced no hearth impairment.

tripeptide; Ser-Asp-Lys; SDK; proliferation inhibition

nije evidentirano